FEV1/FVC Ratio Calculator

How to Use This Calculator

1. Enter FEV1 (L), FVC (L), and FEV1 % predicted (for GOLD staging).
2. Fixed ratio tab uses GOLD <0.70 threshold; LLN tab adjusts for age and sex.
3. Post-bronchodilator tab: enter pre and post values to check reversibility.

Formula

Example

Frequently Asked Questions

• What does the FEV1/FVC ratio measure? ▼
  The FEV1/FVC ratio — also called the Tiffeneau-Pinelli index — is the core spirometric measure for detecting obstructive airway disease. FEV1 (Forced Expiratory Volume in 1 second) is the volume of air exhaled in the first second of a maximal forced expiration from full inspiration. FVC (Forced Vital Capacity) is the total volume exhaled during a maximal forced breath. In healthy adults, FEV1/FVC is typically 0.75–0.85 (75–85%). Airway obstruction — caused by increased airflow resistance as in COPD or asthma — disproportionately reduces FEV1 relative to FVC, lowering the ratio. The ratio is therefore the primary criterion for diagnosing obstruction. Conversely, in restrictive lung diseases (pulmonary fibrosis, sarcoidosis), both FEV1 and FVC fall proportionally, so the ratio remains normal (≥0.70) while absolute volumes are reduced. Confirming restriction requires measurement of Total Lung Capacity (TLC) by body plethysmography or gas dilution, which cannot be assessed by the FEV1/FVC ratio alone. Spirometry should be performed according to ATS/ERS standards: minimum three acceptable manoeuvres, best FEV1 and FVC from any acceptable effort, post-bronchodilator values preferred for COPD diagnosis.
• Why is <0.70 the cutoff for COPD? ▼
  The fixed post-bronchodilator FEV1/FVC ratio below 0.70 is the GOLD (Global Initiative for Chronic Obstructive Lung Disease) diagnostic threshold for airflow limitation in COPD, adopted because it is a simple, reproducible, and internationally consistent criterion. It was chosen based on population data showing that ratios below 0.70 identify individuals at substantially elevated risk of COPD-related outcomes. However, the fixed 0.70 threshold has a recognised limitation: because FEV1/FVC naturally declines with age (by approximately 0.003 per year after age 40), using a fixed ratio over-diagnoses COPD in elderly individuals — up to 35% of healthy adults over 70 may have a ratio below 0.70 without true disease — while potentially under-diagnosing younger adults. The Lower Limit of Normal (LLN) approach uses the 5th percentile of predicted values (age- and sex-adjusted) and avoids this bias, but is more complex to apply. Both GOLD and ATS/ERS acknowledge the limitation of the fixed ratio; LLN-based diagnosis is preferred in epidemiological studies and in patients younger than 45 or older than 70. For clinical practice and regulatory purposes (disability assessment, spirometry-gated treatment criteria), the fixed 0.70 threshold remains the standard because of its simplicity.
• What is the difference between fixed ratio and LLN approach? ▼
  The fixed ratio approach classifies any FEV1/FVC below 0.70 as obstructive, regardless of the patient's age, sex, height, or ethnicity. It is simple, requires no reference tables, and is the method used by GOLD guidelines and most clinical practice guidelines. Its main limitation is age-related over-diagnosis: a healthy 75-year-old man with a FEV1/FVC of 0.68 may be incorrectly labelled obstructive when his ratio is simply at the lower end of normal for his age group. The LLN (Lower Limit of Normal) approach uses the 5th percentile of a reference population (such as NHANES III or GLI-2012) specific to the patient's age, sex, height, and ethnicity. Any ratio below this threshold is abnormal by definition. LLN correctly identifies true outliers at all ages and is favoured by the ATS/ERS, American Thoracic Society official position, and most academic pulmonologists for epidemiological and occupational medicine purposes. The practical trade-off is complexity: LLN requires access to reference equation software or tables. For clinical decision-making in middle-aged adults (40–65 years) both methods yield similar results. The difference is most pronounced in the elderly (where fixed ratio over-diagnoses) and young adults (where fixed ratio may under-diagnose). GOLD acknowledges both approaches and recommends post-bronchodilator spirometry to confirm the diagnosis.
• How is GOLD staging determined? ▼
  GOLD staging classifies the severity of airflow limitation in patients who already meet the diagnostic criterion of FEV1/FVC < 0.70 post-bronchodilator. The four stages are based solely on FEV1 % predicted: GOLD 1 (Mild): FEV1 ≥ 80% predicted; GOLD 2 (Moderate): FEV1 50–79% predicted; GOLD 3 (Severe): FEV1 30–49% predicted; GOLD 4 (Very Severe): FEV1 < 30% predicted. It is important to note that since GOLD 2017, spirometric severity alone is not sufficient to guide treatment decisions. GOLD has replaced the spirometry-based "ABCD" groups with a combined assessment that incorporates symptom burden (mMRC dyspnea scale or CAT score) and exacerbation history. Patients with high exacerbation frequency or hospitalisations for COPD are at higher risk regardless of FEV1 stage. Current GOLD ABCD assessment: Group A (low symptoms, low risk) → bronchodilator monotherapy; Group B (high symptoms, low risk) → LAMA or LABA; Group E (high exacerbation risk, any symptom level) → LAMA+LABA ± ICS. FEV1 staging remains important for prognosis, treatment escalation thresholds, and selecting candidates for interventional procedures such as bronchoscopic lung volume reduction or lung transplantation.
• Can FEV1/FVC differentiate COPD from asthma? ▼
  The FEV1/FVC ratio alone cannot reliably differentiate COPD from asthma, but the pattern of reversibility provides the most useful spirometric distinction. The key differentiator is the post-bronchodilator response: in asthma, FEV1 typically increases by ≥12% and ≥200 mL after short-acting bronchodilator (salbutamol 400 mcg), often restoring the ratio to ≥0.70, whereas in COPD the airflow limitation is largely fixed and post-bronchodilator improvement is usually smaller (though overlap exists). However, up to 30–40% of COPD patients show significant bronchodilator reversibility, and some asthma patients develop fixed obstruction (airway remodelling), so reversibility alone is not definitive. Other distinguishing features include: age of onset (asthma often younger; COPD typically over 40); smoking history (essential for COPD); atopy/allergy history (suggests asthma); clinical course (asthma variable, episodic; COPD progressive); diffusing capacity (DLCO): reduced in emphysematous COPD, normal or elevated in asthma; blood/sputum eosinophilia (asthma); CT chest showing emphysema or bronchiectasis (COPD). "Asthma-COPD Overlap Syndrome" (ACOS) exists when features of both are present. GINA and GOLD recommend spirometry combined with clinical assessment for diagnosis; neither condition should be diagnosed on spirometry alone.

Related Calculators